AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,400.00p
   
  • Change Today:
    -44.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,667.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.62m
  • Volume: 2,797,657
  • Market Cap: £161,265m
  • RiskGrade: 123

Latest ShareCast News

AstraZeneca receives positive Phase III trial results from Enhertu study

By Iain Gilbert

Date: Tuesday 22 Apr 2025

(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it had received "positive high-level results" from a Phase III trial on its Enhertu candidate, developed in conjunction with Daiichi Sankyo.

AstraZeneca Regulatory News

Enhertu combination improved PFS in 1L HER2+ mBC 22-Apr-2025 07:00 RNS
Result of AGM 11-Apr-2025 17:30 RNS
Imfinzi approved in EU for AEGEAN 04-Apr-2025 07:05 RNS
Enhertu approved in EU in post-ET breast cancer 04-Apr-2025 07:00 RNS
Total Voting Rights 01-Apr-2025 15:00 RNS

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,400.00p
Change Today -44.00p
% Change -0.42 %
52 Week High 13,276.00
52 Week Low 9,667.00
Volume 2,797,657
Shares Issued 1,550.62m
Market Cap £161,265m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.47% below the market average94.47% below the market average94.47% below the market average94.47% below the market average94.47% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
28.14% below the market average28.14% below the market average28.14% below the market average28.14% below the market average28.14% below the market average
29.17% above the sector average29.17% above the sector average29.17% above the sector average29.17% above the sector average29.17% above the sector average
Income
64.53% below the market average64.53% below the market average64.53% below the market average64.53% below the market average64.53% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
85.89% above the market average85.89% above the market average85.89% above the market average85.89% above the market average85.89% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 14
Neutral 4
Sell 0
Strong Sell 1
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 25-Apr-2025

Time Volume / Share Price
17:31 99 @ 10,472.38p
17:31 335 @ 10,472.03p
17:31 100 @ 10,471.82p
17:31 139 @ 10,471.88p
11:12 800,000 @ 10,470.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page